Physician profile
Rex Moss
NPI 1265400816
$2,246.32
in general payments reported to CMS, 2019-2025
24 companies · $614 in 2025
The $614 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $50.73 · 2021: $233 · 2022: $400 · 2023: $334 · 2024: $310 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,257.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $646.38 | 2019-2025 | |
| Abbvie INC. | $237.47 | 2021-2025 | |
| Amgen INC. | $194.43 | 2019-2025 | Krystexxa, Evenity |
| Novo Nordisk INC | $194.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.93 | 2019-2025 | Jardiance, Jascayd |
| Glaxosmithkline, LLC. | $132.94 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Sanofi-Aventis U.S. LLC | $115.68 | 2021 | |
| Astellas Pharma US INC | $106.04 | 2019-2023 | Veozah |
| Astrazeneca Pharmaceuticals LP | $99.95 | 2019-2023 | Farxiga |
| Abbott Laboratories | $95.46 | 2025 | Freestyle Libre 3, Eterna, Esprit |
| Amarin Pharma, INC. | $39.85 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.27 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.21 | 2021-2022 | |
| Corcept Therapeutics | $23.88 | 2025 | Korlym |
| Madrigal Pharmaceuticals | $23.70 | 2025 | Rezdiffra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $17.38 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $15.70 | 2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $14.24 | 2021 | |
| Antares Pharma, INC. | $14.22 | 2025 | Xyosted |
| Acella Pharmaceuticals, LLC | $13.87 | 2023 | NP Thyroid 60 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.84 | 2023 | Xifaxan |
| Alnylam Pharmaceuticals INC. | $13.55 | 2022 | |
| Genentech USA, INC. | $11.41 | 2019 | |
| Sanofi Pasteur INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rex Moss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.